Clinical effect of Acostream thrombus aspiration device on early acute superior mesenteric artery embolism.
Abstract
Objective
To investigate the feasibility, safety and efficacy of Acostream thrombus aspiration device in the treatment of early acute superior mesenteric artery embolism.
Methods
A total of 51 patients with ASEAE in our hospital from May 2020 to May 2025 were enrolled, and their clinical data were retrospectively analyzed. According to different surgical methods, 27 cases were treated with Acostream thrombus aspiration device ((PCDT group), 24 cases were treated with catheter thrombolysis (CDT group). Clinical efficacy and surgical complications were observed and evaluated.
Results
All patients successfully completed the thrombolysis therapy, the technical success rate was 100%. There was no significant difference in basic data between the two groups (P > 0.05), the intervention time and abdominal pain relief time of Acostream group were shorter than those of catheter-thrombolytic group (1.20 ± 0.08 h vs 78.87 ± 13.30 h 、1.26 ± 0.32 h vs 25.00 ± 3.67 h P < 0.05).
Conclusion
For acute superior mesenteric artery embolism, the clinical efficacy of Acostream thrombus aspiration is faster and safer than catheter thrombolysis.